The company said, “Senseonics (SENS) generated preliminary unaudited revenue of approximately $8.1 million in the third quarter of 2025, an increase of 91% versus the third quarter of 2024, driven by approximately 160% new patient growth in the U.S. over the prior year. New patient growth has accelerated as a result of increased investment in direct-to-consumer marketing, with the highest number of monthly new patient starts in the Company’s history occurring in September 2025.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SENS:
- Senseonics Approves Reverse Stock Split Proposal
- Positive Outlook on Senseonics Holdings Driven by Eversense 365’s Market Adoption and Growth Potential
- Strategic In-House Transition and Financial Strength Bolster Senseonics’ Growth Outlook
- Senseonics Expands Debt Facility with Hercules Capital
- Senseonics Holdings’ Strategic Shift: Balancing Revenue Growth and Operating Costs Amid In-House Transition